Aims: To assess the safety and efficacy of omarigliptin in Japanese patients with type 2 diabetes (T2D).
stimulate insulin secretion and (in the case of GLP-1) decrease glucagon release in a glucose-dependent manner. 2 Over the past decade, daily-dosed DPP-4 inhibitors have become an established part of the therapeutic armamentarium for the treatment of T2D. 3 In the present paper, we report the results of a phase III trial conducted in Japanese patients that included a 24-week double-blind, placebo-and sitagliptin-controlled period (double-blind period) and a subsequent 28-week open-label extension (open-label period) in which all patients received omarigliptin. The rationale for the trial, which supported registration in Japan, was to assess the glycaemic efficacy of omarigliptin compared with placebo and a once-daily DPP-4 inhibitor.
The objectives of the trial were to assess the safety, tolerability and efficacy of omarigliptin 25 mg once weekly compared with placebo and sitagliptin 50 mg once daily over 24 weeks and to obtain longer-term (52-week) data on omarigliptin 25 mg once weekly during the open-label extension. The hypotheses tested in the present trial were that: (1) after 24 weeks, omarigliptin 25 mg once weekly is superior to placebo in reducing glycated haemoglobin (HbA1c), 2-hour postprandial glucose (PPG), and fasting plasma glucose (FPG) levels and (2) after 24 weeks, omarigliptin is non-inferior to sitagliptin 50 mg once daily in reducing HbA1c.
| RESEARCH DESIGN AND METHODS

| Patients
Trial patients were Japanese men and women, aged ≥20 years, with T2D and a body mass index >18 and <40 kg/m 2 . At the screening visit, patients who were treatment-naïve (never on an oral antihyperglycaemic agent [AHA]) or off AHA medication for ≥6 weeks and had National Glycohemoglobin Standardization Program (NGSP) HbA1c ≥7.0% and ≤10.0% were eligible for the study; those on oral AHA medication monotherapy with an NGSP HbA1c ≥6.5% and ≤9.0%, and after a 6-week AHA wash-out period, NGSP HbA1c
≥7.0% and ≤10.0%, were also eligible for the study. At week −2, patients were required to have an HbA1c level between ≥7.0% and ≤10.0% and an FPG level ≤12.8 mmol/L.
Patients were excluded from the study if they had type 1 diabetes, a history of ketoacidosis, active liver disease, significant cardiovascular disease, a history of malignancy or haematological disorders, or had been previously treated with sitagliptin or omarigliptin at any time, or with thiazolidinediones or insulin therapy within 12 weeks prior to the screening visit.
Laboratory exclusion criteria included estimated glomerular filtration rate <50 mL/min/1.73 m 2 , alanine aminotransferase or aspartate aminotransferase >2 times the upper limit of normal, triglycerides >6.78 mmol/L or thyroid-stimulating hormone outside the central laboratory normal range.
| Study design
The study was a randomized, placebo-and sitagliptin-controlled, parallel-group, multicentre, double-blind trial of omarigliptin 25 mg once weekly, with an open-label extension in which all patients received omarigliptin 25 mg once weekly ( Figure S1 ). The study included a screening period of up to 2 weeks, a wash-out period of 6 weeks for patients on an oral AHA, a 2-week single-blind placebo run-in period, and a 24-week double-blind treatment period followed by a 28-week open-label extension period. At randomization, patients
were stratified according to their use of oral AHA at screening.
Patients were randomized using a double-dummy design in a 2 
| Study evaluations
The primary objectives of the present study were to assess the safety and efficacy of omarigliptin for a period of 24 weeks compared with placebo and sitagliptin and to assess the longer-term safety and toler- 
| Efficacy endpoints
Changes from baseline in HbA1c, 2-hour PPG and FPG levels after 24 and 52 weeks of treatment were calculated. The percentages of patients at HbA1c goals of <7.0% and <6.5% at weeks 24 and 52 were also calculated.
| Safety endpoints
Safety endpoints included the incidence rates of adverse events (AEs), percentages of patients meeting predefined limits of change in laboratory variables, change from baseline at weeks 24 and 52 in laboratory variables, ECG, vital signs and body weight. A predefined AE of interest was symptomatic hypoglycaemia. Secondary efficacy endpoints (2-hour PPG and FPG) were analysed using the LDA model described for HbA1c.
| Statistical analyses
The exploratory endpoint of omarigliptin efficacy up to week 52 was analysed using the LDA model described above (without explicit imputation of missing data) and by calculation of arithmetic means at each time point (without imputation of missing data or adjustment for any factors). Only within-group analyses were performed because there was no control group in the extension period during which all the patients were treated with omarigliptin.
Analysis of percentages of individuals at the HbA1c goals of <7.0% and <6.5% at weeks 24 and 52 were conducted using the stratified (by prior AHA therapy status) Miettinen and Nurminen method. 5 Multiple imputations, based on the LDA model for the analyses of HbA1c, were used to handle missing data. 6 Each patient was categorized as a responder (satisfying the HbA1c [NGSP] specific goal of <7.0% or <6.5%) or non-responder at weeks 24 or 52.
With the exception of the cross-treated patient noted above, the population of all randomized patients who received at least 1 dose of study treatment was used for the analysis of safety data. Safety and tolerability were assessed by clinical review of all relevant variables including AEs, laboratory tests, ECG, vital signs and body weight. AEs of symptomatic hypoglycaemia were prespecified as events of interest and P values and 95% CIs for between-treatment group comparisons were calculated using the method of Miettinen and Nurminen. 5 For all other endpoints, summary statistics were generated. Change from baseline in body weight at week 24 was analysed using the LDA model described for HbA1c.
To evaluate the longer-term safety of omarigliptin, the incidence rates (%) of AEs were calculated for the group receiving omarigliptin during the entire duration of the study. Between-group comparisons and/or estimations of between-group differences were not per-
formed for the open-label period. Change from baseline in body weight up to week 52 was analysed as at week 24.
In both phases of this study, potential cases of pancreatitis and prespecified hypersensitivity AEs (anaphylactic reaction, angioedema, asthma-bronchospasm, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms) were evaluated in a blinded manner by external clinical adjudication committees.
3 | RESULTS
| Patient disposition and characteristics
A total of 531 patients were screened and 414 patients were rando- (Table 1) .
| Efficacy in the double-blind period
After 24 weeks of treatment, omarigliptin treatment provided a greater reduction in HbA1c compared with placebo (Table 2; P < .001), and omarigliptin treatment provided non-inferior reductions in HbA1c compared with sitagliptin treatment (Table 2; 12 and, at later timepoints, the differences in point estimates for FPG were less notable.
At the end of the double-blind treatment period, the percentages of patients reaching the HbA1c goals of <7.0% and <6.5% were higher in both active treatment groups compared with placebo ( Figure 2) . At week 24, 47% and 38% of patients in the omarigliptin and sitagliptin groups, respectively, had HbA1c <7.0% compared with 7% of patients in the placebo group (nominal P < .001 in both cases), while 10% and 9% of patients in the omarigliptin and sitagliptin groups, respectively, had HbA1c <6.5%, compared with 1% of patients in the placebo group (nominal P = .009 and .027 for the omarigliptin and sitagliptin groups, respectively).
| Efficacy in the open-label period
The overall efficacy was derived from both the model-based LDA method and a simple analysis of mean values (arithmetic mean) from available data without adjustment for any factors (Table S1 and sitagliptin/omarigliptin groups were similar over time ( Figure S3A ,B).
In the placebo/omarigliptin group improvements in glycaemic variables were observed within 4 weeks of the switch from placebo to omarigliptin and at week 52 the changes were similar to the other treatment groups.
At week 52, the reductions from baseline in 2-hour PPG were similar in all three treatment groups (Table S1 ).
At the end of the open-label period treatment, the percentages of patients reaching the HbA1c goal of <7.0% were 35%, 25% and 32% in the omarigliptin/omarigliptin, sitagliptin/omarigliptin and placebo/omarigliptin groups, respectively. The percentages of patients reaching the HbA1c goal of <6.5% were 7%, 7% and 9%, in the same groups, respectively.
| Safety 3.4.1 | Double-blind period
The incidence rates of AEs, including those that were assessed by the investigator as drug-related, serious AEs (SAEs), and AEs leading to discontinuation were generally similar between the omarigliptin and sitagliptin groups (Table 3 ). There were no notable differences in the incidence rates of specific AEs in the omarigliptin and sitagliptin groups compared with the placebo group. The incidence rates of specific AEs with an incidence ≥3% are shown in Table 3 . No serious drug-related AEs or deaths were reported in any treatment group.
There were no events of symptomatic hypoglycaemia in the omarigliptin or placebo treatment groups and 1 event in the sitagliptin group (Table 3) . No severe hypoglycaemia episodes (any episode of hypoglycaemia for which assistance was required) were reported.
There were no investigator-reported cases or adjudication-confirmed cases of acute or chronic pancreatitis or serious hypersensitivity. No notable difference was observed in the percentage of patients that met the QTc predefined limits of change criteria among the treatment groups. As noted in the Statistical Analysis section, 1 patient in the study who was cross-treated with omarigliptin and then with placebo and then discontinued by the investigator was not included in the overall safety analysis. In this patient, a non-serious AE of herpes zoster was reported on day 22 (at which time the patient was exposed to incorrectly dispensed omarigliptin). The event was mild in intensity and resolved on day 57. No action was taken with the study medication and the event was assessed by the investigator as not-related to the study medication.
| Safety in the open-label period
Only the group initiating omarigliptin during the double-blind period could provide safety data for longer-term (52-week) omarigliptin treatment. In this group, the overall incidence of AEs was 116/166 patients (69.9%), the incidence of drug-related AEs was 13/166 patients (7.8%) and the incidence of SAEs was 6/166 patients (3.6%; Table S2 ). Of these, 3 patients experienced SAEs during the first 24 weeks. One SAE (prostate cancer) was reported in the omarigliptin (Table S2 ). There were no adjudicationconfirmed cases of acute or chronic pancreatitis or prespecified hypersensitivity adverse reactions. Adverse events summary: incidences of specific AEs a with incidence ≥3% in ≥1 treatment group and incidence rates for symptomatic hypoglycaemia up to week 24 (double-blind period) b Assessed by the investigator as related to study drug.
c One additional patient, in whom a SAE of "bile duct stone" was reported, discontinued during the double-blind period of the study. The patient's discontinuation from study was initially reported as attributable to discontinuation criterion related to increased hepatic enzymes (the elevated hepatic enzymes were not reported as an AE). After unblinding this was updated to indicate that the patient's discontinuation from study was attributable to the SAE; therefore, this patient is not included in this table as discontinued because of an AE/SAE, but is included as discontinued because of an AE/ SAE in the week 52 summary (Table S2 ).
d Prespecified AE of interest; symptomatic hypoglycaemia: episode with clinical symptoms attributed to hypoglycaemia, without regard to glucose level.
discordance in FPG was observed among the treatment groups at 6 and 12 weeks (visit intervals were different in the 2 studies). The results of the double-blind and open-label periods of the study indicated that weekly treatment with omarigliptin 25 mg was well tolerated. During the double-blind period, there were no notable differences in the overall incidence rates of AEs or drug-related AEs between the omarigliptin and sitagliptin groups. The overall incidence rates of AEs or drug-related AEs were not unexpectedly increased during longer-term treatment with omarigliptin up to 52 weeks. During the double-blind period, no notable difference was observed between treatment groups in the incidence rates of SAEs or in the incidence of patients discontinued from study medication because of
AEs. The incidence rates of SAEs or AEs leading to discontinuation were low up to 52 weeks of treatment.
The absence of symptomatic hypoglycaemia throughout the 52-week treatment period in the group treated with omarigliptin is consistent with the known low incidence of hypoglycaemia when daily DPP-4 inhibitors are administered as monotherapy or co-administered with agents that are not by themselves associated with hypoglycaemia. 10 In recent years, a patient-centred approach has been recommended for the treatment of T2D. 3 Available evidence suggests that weekly administered AHAs are viewed positively by patients with T2D [11] [12] [13] [14] ; therefore, a once-weekly oral AHA may be a therapeutic option when the patient prefers a weekly regimen. Since effective treatment of T2D can be complicated by poor medication adherence, [15] [16] [17] [18] a once-weekly AHA may also have advantages when poor patient adherence to medication has been identified as a barrier to achieving therapeutic goals. A weekly oral AHA may also be useful in other clinical situations (e.g., intermittent assisted healthcare).
The strength of the present trial is that it included both placebo and sitagliptin comparator arms, which allowed an assessment of intrinsic efficacy (placebo comparison) and a direct comparison with the relevant dose of a daily DPP-4 inhibitor. One limitation of the trial is that patient compliance may have been higher than that which might be observed in real-world settings. In addition, patient satisfaction with a once-weekly AHA could not be assessed because to maintain double-blinding in the placebo-controlled portion of the trial all treatment groups took once-weekly (omarigliptin or matching placebo) and once-daily (sitagliptin or matching placebo) trial medication.
In conclusion, the results of the present study suggest that omarigliptin is an efficacious and generally well-tolerated, weekly oral AHA for treatment of Japanese patients with T2D. Real-world studies would be useful to further evaluate the potential benefits of onceweekly treatment with regard to compliance and satisfaction.
